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We here use knockin mutagenesis in the mouse to model the spectrum of acquired CEBPA mutations in
human acute myeloid leukemia. We find that C-terminal C/EBPa mutations increase the proliferation of
long-term hematopoietic stem cells (LT-HSCs) in a cell-intrinsic manner and override normal HSC homeo-
stasis, leading to expansion of premalignant HSCs. However, such mutations impair myeloid programming
of HSCs and block myeloid lineage commitment when homozygous. In contrast, N-terminal C/EBPa muta-
tions are silent with regards to HSC expansion, but allow the formation of committed myeloid progenitors,
the templates for leukemia-initiating cells. The combination of N- and C-terminal C/EBPamutations incorpo-
rates both features, accelerating disease development and explaining the clinical prevalence of this config-
uration of CEBPA mutations.INTRODUCTION
A large body of evidence indicates that acute myeloid leukemia
(AML) arises through the stepwise acquisition of genetic and
epigenetic changes. In particular, tumorigenesis is promoted by
the collaboration between mutations affecting signaling path-
ways (class I or signaling mutations; FLT3, RAS and KIT muta-
tions) andmutationswith a transcriptional/nuclear function (class
II or initiating mutations, balanced translocations, and CEBPA
and NPM1 mutations) (Kelly and Gilliland, 2002; Moore, 2005).
Because the hematopoietic stem cell (HSC) is the only long-lived
cell within the myeloid differentiation hierarchy, it is the primary
candidate cell for the accumulationof these successive leukemo-
genic events. Studies of AML patients relapsing from complete
remission after chemotherapy are consistent with class II (or initi-
ating) mutations, including balanced translocations and CEBPA390 Cancer Cell 16, 390–400, November 3, 2009 ª2009 Elsevier Incmutations, being very early events in this process, because these
events are generally conserved in the relapse tumor (Shih et al.,
2006). In contrast, KIT, FLT3, and RAS mutations (class I or
signaling mutations) frequently differ between initial and relapse
tumors (Kottaridis et al., 2002; Shih et al., 2002, 2004), indicating
that they occur subsequently to the highly conserved class II
mutations.However, despite the inferred founding nature of class
IImutations, limited information exists about their effect onHSCs,
and in particular their ability to cause expansion of premalignant
stemcell populations, thereby increasing theprobability of acqui-
sition of collaborating genetic/epigenetic events.
This issue has been highlighted by the recent controversy
regarding the role of theHSC compartment in AMLmaintenance.
The original observations by Dick and colleagues identified
the leukemia-initiating cell (LIC) as CD34+CD38 (Bonnet and
Dick, 1997; Lapidot et al., 1994), consistent with an immatureSIGNIFICANCE
Acquired mutations in the CEBPA gene occur in ca. 9% of human AML patients. However, so far no explanation existed for
the observation that ca. 90% of patients have distinct mutations on the two CEBPA alleles. Our findings provide a cellular
basis for the observed clinical mutation pattern. Significantly, the leukemia-initiating cells that develop in mice with HSC
expansion are committed progenitors, suggesting that leukemogenic mutations may have crucial functions in cell types
not found in the final transformed clone. Finally, we demonstrate that impaired myeloid lineage commitment of Cebpa
mutant HSCs is preceded by a loss of myeloid gene expression at the HSC level, providing a link betweenmyeloid program-
ming of HSCs and their lineage potential..
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HSC Expansion in C/EBPa Mutant AMLHSC-like phenotype. Here mutations that increase HSC prolifer-
ation and/or self-renewal would provide a selective advantage to
premalignant HSCs, and in cooperation with second hits lead to
transformation. However, recent results indicate that the lack of
detectable LIC activity in the CD34+CD38+ progenitor fraction
was due primarily to Fc-mediated immune clearance of anti-
CD38 conjugated cells. If this is circumvented, LICs with a
myeloid progenitor phenotype (CD34+CD38+) are more abun-
dant in the majority of AML cases studied (Taussig et al.,
2008). In such a scenario, premalignant HSC expansion, lineage
commitment, and target cell transformation could become rate-
limiting features of initiating mutations, requiring the effects of
oncogenic mutations on several aspects of hematopoiesis to
be examined. For proper assessment of these effects, the
disease models need to model the human disease as accurately
as possible. As an example, viral expression of MLL-AF9 allows
leukemia initiation from a committed granulocyte-macrophage
progenitor (GMP) (Cozzio et al., 2003), whereas a knockinMll-Af9
allele, driven by the endogenous Mll1 promoter, could initiate
AML only from HSCs (Chen et al., 2008), presumably because
of the low activity of theMll1 promoter in myeloid progenitors.
This consideration is particularly relevant in the case ofCEBPA
mutations because deletion of the Cebpa gene from murine
HSCs was found to make HSCs more competitive against
wild-type HSCs (Zhang et al., 2004). Although this would be
consistent with CEBPA mutations having a similar function in
preleukemic HSCs, such an interpretation is complicated by
the finding that leukemia-derived CEBPA mutations are virtually
never null mutations. Rather, CEBPA mutations are divided into
two major groups: N-terminal mutations that block the transla-
tion of the 42 kDa isoform (p42) while allowing the 30 kDa isoform
(p30) to be expressed and C-terminal mutations that generate in-
frame insertions/deletions within the basic region-leucine zipper
DNA binding domain (Leroy et al., 2005; Nerlov, 2004). Notably,
>90% of leukemias with bialleleic CEBPA mutations harbor one
allele with a C-terminal mutation and one with an N-terminal
mutation, indicating selection of this mutation pattern during
tumorigenesis. In contrast, tumors with homozygous N- or
C-terminal mutations are comparatively rare (Pabst and Mueller,
2007). This indicates that the two mutations provide distinct
leukemogenic functions and thus are able to collaborate. The
importance of specific alterations of C/EBPa function is further
supported by the finding that complete deletion of Cebpa does
not lead to leukemia in the mouse (Heath et al., 2004; Zhang
et al., 2004). C/EBPa is generally considered an inducer of
terminal differentiation due to its ability to couple induction of
cell-type-specific gene expression to cell-cycle arrest (Nerlov,
2007), and in the mouse Cebpa mutations that impair E2F
repression by C/EBPa increase myeloid progenitor proliferation
(Kirstetter et al., 2008; Porse et al., 2005) and impair terminal
granulopoiesis (Porse et al., 2001). Complete deletion of Cebpa
blocks the formation of GMPs and thus myeloid lineage commit-
ment (Zhang et al., 2004). However, despite the relevance of C/
EBPa to HSC function, little is known about its role in HSC gene
expression, and how this may impact proliferation, lineage
commitment, and leukemogenesis. In particular, the complex
nature of AML-derived CEBPA mutations indicates a need to
understand the specific impact of patient-derived mutant alleles
on HSC homeostasis and the myeloid differentiation pathway.CRESULTS
To resolve this question, we decided to generate an accurate
mouse model for the spectrum of CEBPA mutations occurring
in AML (Figure 1A). We generated a knockin allele mimicking
one of the common C-terminal mutations (K313 duplication:
K313KK or K allele; Figure 1B). By combining this mutation
with an existing knockin of an N-terminal mutation (Lp30 or L
allele [Kirstetter et al., 2008]) (Figure 1B), the spectrum of patient
mutations could be generated. Fetal liver (FL) cells fromK/K, K/L,
L/L, and +/+ mice (CD45.2 allotype) were competitively trans-
planted into lethally irradiated CD45.1/2 recipients along with
CD45.1 wild-type competitor bone marrow cells (Figure 1C). In
this manner, lethality due to dysfunction of Cebpa mutant cells
was avoided, and mutant HSC behavior could be studied while
competing with wild-type HSCs, a situation more similar to that
encountered in thepremalignantstate. Importantly, the frequency
of phenotypic HSCs in the FL, measured either as Lin Sca-1+
c-Kit+ cells (LSK cells; data not shown) or LSKAA4.1+ cells (repo-
pulating HSC fraction (Jordan et al., 1995); Figure 1D), did not
differ between the mutant genotypes.
Analysis of mice 4.5 weeks after competitive transplantation
revealed that the frequency of LSK cells was increased relative
to +/+ controls in K/L and K/K (but not L/L) mice, indicating
loss of HSC homeostasis (Figure 2A). This increase was due to
specific expansion of the mutant HSC pool (Figure 2B), demon-
strating a cell-intrinsic effect of theseCebpamutations. Fraction-
ation of the experimental (CD45.2+CD45.1) HSC compartment
using CD150 and Flt3 expression (Figure 2C) showed expansion
of all phenotypic HSC subsets, most significantly the short-term
(ST)-HSC (CD150–Flt3) and lymphoid-primed multipotent
progenitor (LMPP) (CD150Flt3+) populations, although mild
expansion was observed also of long-term (LT)-HSCs (CD150+
Flt3) (Figure 2D). Interestingly, K/+ HSCs did not expand in
this setting (see Figure S1 available online), suggesting that
mutation of both Cebpa alleles is required for the effect of
C-terminal C/EBPa mutation on HSC expansion to take effect.
Importantly, Cebpa mRNA was expressed in all three HSC frac-
tions (Figure 2E), consistent with the effects of Cebpa mutation
being cell intrinsic.
To probe the molecular basis for the observed HSC expan-
sion, we performed Affymetrix-based global gene expression
analysis on sorted CD45.2+CD45.1 LSK cells from competi-
tively transplanted animals. LIMMA analysis of differentially ex-
pressed genes (Table S1) followed by unsupervised clustering
showed that the nonhomeostatic K/L and K/K LSK populations
coclustered, as did the L/L and +/+ LSK cells (Figure 3A). Gene
expression signatures of expanding HSC populations have
been generated by microarray analysis of the quiescence-prolif-
eration-quiescence sequence induced by 5-fluorouracil treat-
ment (Venezia et al., 2004). Using gene set enrichment analysis
(GSEA), we observed that the expression of quiescence-associ-
ated genes (Q-Sig) was significantly decreased in expanding
(K/K and K/L) relative to homeostatic (L/L and +/+) LSK cells,
whereas no significant enrichment of proliferation-associated
gene expression was observed (Figure 3B). Comparison of indi-
vidual mutant LSK populations to +/+ LSK cells showed that K/K
and K/L LSK cells, but not L/L LSK cells, were depleted of Q-Sig
genes (Figure 3C). Because the LT-HSC population gives rise toancer Cell 16, 390–400, November 3, 2009 ª2009 Elsevier Inc. 391
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(A) Schematic representation of C/EBPa protein isoforms occurring naturally
(p42 and p30) and as a result of AML associated mutations. BR, basic region;
LZ, leucine zipper.
(B) Schematic representation of mutant Cebpa alleles. Closed triangles,
LoxP sites; open box, neomycin cassette; duplicated lysine residue is shown
in red.
(C) Experimental design for generation of radiation chimeras to study the effect
of compound Cebpa mutations on hematopoiesis. A total of 1.25 3 105 fetal
liver (FL) cells (Ly5.2 allotype and indicated genotypes) were tail vain injected
into lethally irradiated recipients (CD45.1/2 allotype) along with 5 3 105 wild
type helper bone marrow (BM) cells (CD45.1 allotype).392 Cancer Cell 16, 390–400, November 3, 2009 ª2009 Elsevier Inc.the other LSK subsets, any defect in proliferation control could
originate in this cell population. Similar gene profiling of K/L
against +/+ control LT-HSCs (Table S2) showed that Q-Sig
genes were also depleted in Cebpa mutant cells (Figure 3D).
To address whether depletion of the quiescence signature
was associated with increased proliferation, we performed flow
cytometry-based cell-cycle analysis. Through intracellular stain-
ing for Ki67 and DNA content (using DAPI), we could define G0
HSCs (Ki67, 2n DNA content), G1 (Ki67+, 2n), and S/G2/M
(Ki67+, > 2n) populations within the HSC subfractions (Figure 3E).
The K/L and K/K mutant HSCs showed a decreased G0 fraction,
and correspondingly increased G1 and/or S/G2M fractions in
LT-HSCs (Figure 3F). Similar results were obtained for the other
HSC subsets (Figures 3G and 3H), whereas L/L HSCs did not
differ significantly from +/+ controls. We were therefore able to
conclude that introduction of the K/K or K/L mutations into the
HSC compartment caused expansion of the mutant HSC/multi-
potent progenitor (MPP) containing LSK population through
a cell-intrinsic mechanism, mediated in part by decreased quies-
cence of Cebpa mutant phenotypic LT-HSCs and their down-
streamprogeny. This expansiondid not continue in theprogenitor
compartment because the LinSca-1c-Kit+ populations were
proportional to the LSK populations (data not shown), indicating
the HSC compartment as the important point of expansion.
Expansion of a premalignant HSC/MPP compartment is a
potentially potent accelerator of leukemogenesis because it
increases the pool of transformable stem cells and/or progeni-
tors. To compare the leukemogenic potential of the different
combinations of Cebpa mutations, we monitored cohorts of
K/K, L/L, K/L, and control +/+ fetal liver transplanted chimeras
for survival and tumor development. All three mutant genotypes
gave rise to lethal leukemias. However, we observed that mice
transplanted with K/L FL cells died significantly more quickly
than the L/L and K/K cohorts (Figure 4A), whereas the K/K
disease development was delayed compared to the other
mutations.We had previously characterized the LIC in L/L homo-
zygous mice as a committed myeloid progenitor (Sca-1
Mac-1lo/+c-Kit+ [Kirstetter et al., 2008]). To determine whether
the accelerated disease induced by the K/L mutation was due
to the transformation of a different target cell, we performed
fractionation of the leukemias into an HSC-containing fraction
(Sca-1+; fraction I), a myeloid progenitor fraction (Sca-1–
Mac-1lo/+c-Kit+; fraction II), and a differentiated tumor cell frac-
tion (Sca-1Mac-1hic-Kitlo/–; fraction III) (Figure 4B). Upon trans-
plantation into lethally irradiated recipients (CD45.1/2) along with
CD45.1 competitor, only fraction II gave rise to lethal leukemia
(Figure 4C) associated with unilineage myeloid engraftment (Fig-
ure 4D). Interestingly, in two of three leukemic mice, the HSC-
containing fraction I yielded long-term multilineage engraftment
(D) Evaluation of frequencies of hematopoietic stem cell in E14.5 FLs of Cebpa
allelic variants and their combination. Live, Lin cells were gated and analyzed
for the expression of the c Kit and Sca 1 surface markers. Linc Kit+Sca 1+
(LSK) cells were gated and further analyzed for the expression of AA4.1 surface
marker. The gating strategy and representative fluorescence activated cell
sorting (FACS) plots are shown for Cebpa wild type (WT) FL. The percentages
of each population relative to whole FL are shown next to each gate. Graphs
below the plots represent average of LSK and LSK AA4.1+ frequencies (five
independent experiments, total of three to nine FLs per genotype). Error
bars represent the standard deviation.
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and data not shown). The more rapid K/L leukemia is thus driven
by a committed myeloid progenitor with leukemia-initiating
activity in the HSC fraction below the limit of detection at the
cell dosage used. Importantly, direct transplantation of sorted
myeloid progenitors (LinSca-1c-Kit+) from K/L FL did not
result in any engraftment, which was observed only when trans-
planting the LSK fraction (data not shown).
These results were consistent with preleukemic HSC expan-
sion accelerating K/L leukemogenesis by generating high
numbers of committed progenitor templates for transformation.
However, the slow progression of the K/K leukemias could not
be explained in this manner. A closer examination of the end-
stage disease revealed that K/L and L/L tumors were virtually
always granulocytic. They contained myeloid blasts in the
Figure 2. Expansion of C/EBPa Mutant
HSCs
(A) Frequency of LSK cells in BM of mice compet
itively transplanted with wild type or Cebpa
mutant FL (genotypes indicated) along with wild
type BM helper cells. Graphs represent average
of three independent experiments, each with three
mice per genotype.
(B) LSK compartment was analyzed for the relative
contribution of FL derived (CD45.2+, black bars)
and helper BM derived cells (CD45.1+, white
bars). Representative dot plots for the LSK gates
and allotype based fractionation of LSK compart
ment are shown below the graph for WT and K/L
FL cell transplanted animals.
(C) LSK CD45.2+ compartment was subfractioned
into LT HSC, ST HSC, and MPP based on the
surface expression of CD150 and Flt3.
(D) Graphs represent frequencies of LSK subpop
ulationswithin CD45.2+ FL derived cells of the four
indicated genotypes (color coded). Data represent
average of two independent experiments, three
mice per genotype with standard deviation and
statistical significance shown (*p < 0.05; **p <
0.005; ***p < 0.0005, t test; error bars indicate
standard deviations). Representative contour
plots of Flt3 and CD150 expression based frac
tionation of CD45.1CD45.2+ LSK cells are shown
below the graph for each of the genotypes.
Numbers within each window represent frequency
of each subpopulation of total bone marrow cells.
(E) Expression of Cebpa mRNA was measured by
TaqMan RT PCR in the LT HSC, ST HSC, and
LMPP fractions. Values represent the average of
three independent sorting experiments, each
measured in triplicate. Values were normalized to
those obtained in the same samples for Hprt
mRNA. In all panels, error bars represent standard
deviations.
peripheral blood (Figure 5A) and showed
partial granulocytic maturation of tumor
cells (Figure 5B), with myeloid infiltrates
of the spleen (Figure 5C) that stained
positive for myeloperoxidase (Figure 5D),
consistent with an FAB M2-like leukemia
(granulocytic with maturation). However,
only 25% of K/K tumors could be classified as myeloid with
maturation based on the above criteria (Figures 5A–5E; K/K-M
phenotype), with the remaining tumors displaying a more imma-
ture phenotype (K/K-I phenotype) with undetectable maturation
or myeloid infiltration. Flow cytometry of the mutant bone
marrow fraction (Figure 5F) confirmed that the K/K-I phenotype
contained very few differentiatingmyeloid cells (Mac-1hic-Kit–/lo).
Rather, the K/K-I mice were characterized by the accumulation
of immature erythroid cells, indicating leukemia with erythroid
lineage involvement (data not shown). These results are summa-
rized in Figure 5G.
This suggested that K/K mutant cells were impaired in the
generation of myeloid tumors with granulocytic maturation,
such as those sustained by the previously characterized
committed myeloid LIC. We have previously found that C/EBPaCancer Cell 16, 390–400, November 3, 2009 ª2009 Elsevier Inc. 393
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HSC Expansion in C/EBPa Mutant AMLknockin mutations specifically increased the proliferative
capacity of committed myeloid progenitors, but not megakaryo-
cyte-erythroid progenitors (Kirstetter et al., 2008; Porse et al.,
2005). If this population were particularly susceptible to transfor-
mation, the ability to form committed myeloid cells would
become rate limiting during tumor development. Because
complete loss of C/EBPa was found to block myeloid lineage
commitment at the CMP-GMP transition, it is possible that the
Figure 3. C terminal Cebpa Mutations Increase HSC Proliferation
(A) Unsupervised clustering of control and Cebpa mutant LSK populations using the union of differences between individual genotypes observed by LIMMA
analysis of all pairwise combinations. The genes were K means clustered (n = 9) and clusters are color coded on the left side bar.
(B) GSEA comparison of the KK+KL genotypes against the LL+WT genotypes for enrichment/depletion of proliferation (proliferation associated gene expression;
left panel) and quiescence (Q Sig; right panel) associated gene expression. The normalized enrichment scores (NES) and p values are indicated on each plot.
(C) Similar analysis as in (B) for Q Sig depletion in pairwise comparisons of WT and KK, WT and KL, and WT and LL (left to right) LSK populations.
(D) Depletion of Q Sig genes in K/L LT HSCs analyzed as in (B).
(E H) Flow cytometric analysis of the cell cycle of FL derived LT HSC, ST HSC, andMPP. Representative contour plots in the top row show the gating strategy for
the analysis (shown for the WT FL cells). Cell cycle phases were defined as G0 (Ki67, DAPIlo), G1 (Ki67+, DAPIlo), and G2/S (Ki67+, DAPIhi) as shown in the right
most dot plot. Representative dot plots for the cell cycle analysis of LT HSC in four indicated Cebpa genotypes are shown in the second row. Numbers close to
each gate show the percentage of cells in a cell cycle phase. Average values (six or seven mice per genotype, two independent experiment) are shown in the
graphs in (F) for LT HSC, (G) for ST HSC, and (H) for LMPPs (*p < 0.05; **p < 0.005; ***p < 0.0005, Student’s t test). In all panels, error bars represent standard
deviations.394 Cancer Cell 16, 390–400, November 3, 2009 ª2009 Elsevier Inc.
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HSC Expansion in C/EBPa Mutant AMLFigure 4. Cebpa Mutant Bone Marrow Chimeras Develop AML
(A) Kaplan Meier survival analysis of mice transplanted with +/+, L/L, K/L, and
K/K FL cells showing the accelerated death in K/L transplanted animals, and
a delay in tumor progression in K/K transplanted mice, each with respect to
L/L transplanted mice. The number of animals from four independent experi
ments is included in the analysis, and the statistical significance (log rank anal
ysis) for mice survival differences is shown to the right of the plot.
(B) Gating strategy for K/L tumor fractionation in tumor retransplantation
experiments. Total BM cells were sorted as fractions I (Lin*Sca 1+), II (Lin* /lo
c Kit+Mac 1 /lo), and III (Lin* /lo c kit Mac 1+). The modified Lin* lineage cock
tail excludes erythroid and lymphoid, but not myeloid, cells. Two thousand
cells of each fraction were transplanted along with 2.5 3 105 helper bone
marrow cells into the tail vein of lethally irradiated recipients, and animals
were monitored for tumor development.
(C) Kaplan Meier survival curve for mice transplanted with cells of fractions I, II,
and III showing lethality only in fraction II transplanted animals.
(D) Representative dot plots of PB analysis fromK/L fraction I (left panels), frac
tion II (middle panels), and fraction III (right panel) transplanted animals at indi
cated time points, showing contribution of helper (CD45.1+) and donor derivedCimmature phenotype and relatively slow progression of K/K
tumorigenesis was due to a block in formation of the committed
myeloid progenitors. Using the classification of Akashi et al.
(2000), we observed that GMP formation (defined as LinSca-1
c-Kit+IL-7raCD34+FcgII/III+) was normal in L/L progenitors
compared with +/+ controls, consistent with our previous results
(Kirstetter et al., 2008). In contrast, GMP levels were lower in K/L
progenitors and virtually absent in K/K progenitors, whereas the
cotransplanted wild-type CD45.1 progenitors differentiated
normally (Figure S2). Similar results were obtained with the
more recent classification of Pronk et al. (2007). Here, GMPs
are defined as LinSca-1c-Kit+CD150FcgII/III+ (Figure 6A).
Importantly, the difference in GMP production between K/L
and K/K progenitors was significant (Figure 6B), and only K/L
progenitors gave rise to detectable myeloid-committed bone
marrow (BM) cells (defined as Mac-1+; Figure 6C), with both
K/K and K/L cells generating similar number of bone marrow
B cells. The lack of myeloid progression of K/K leukemias may
therefore be explained by a severe and persistent block in the
formation of committed myeloid progenitors, which is the cell
population rendered susceptible to transformation by C/EBPa
loss of function (Kirstetter et al., 2008; Porse et al., 2005). In
the absence of committed progenitor transformation, a different,
most likely erythroid, target cell is transformed, but with slower
kinetics or less malignant phenotype, explaining the delay in
K/K tumorigenesis relative to K/L tumors.
HSCs and multipotent progenitors have been observed to
express at low levels genes characteristic of the lineages for
which they have developmental potential, a phenomenon known
as lineage priming (Hu et al., 1997; Mansson et al., 2007).
Because it was recently found that separation of the myeloid
lineages from the lymphoid and megakaryocytic/erythroid
(Mk/E) lineages may occur already within the LSK compartment
(Adolfsson et al., 2005; Pronk et al., 2007), we investigated
whether the myeloid lineage commitment defect in K/K and
K/L progenitors was evident at the HSC level. Using the previ-
ously defined Mk/E and myeloid-specific gene sets to analyze
the LSK microarray data, we observed that myeloid genes
were strongly depleted from K/K and K/L LSK cells (normalized
enrichment scores [NES] < 2.5; p < 0.001), but less severely
so in L/L LSK cells (NES =1.432; p = 0.003) (Figure 6D), mirror-
ing the subsequent lineage commitment defect. Conversely,
MkE programming was significantly increased in K/K LSK cells,
but not in K/L or L/L LSK cells (Figure S3). By dividing the MkE
gene set into an E-specific and Mk-specific component, it was
observed that the MkE enrichment in K/K LSK cells was due to
increased erythroid gene expression (Figure 6E and Figure S3).
We further investigated whether altered lineage programming
was observed in the LT-HSC fraction: in K/L LT-HSCs, GM-
specific genes were significantly depleted and E-specific genes
were upregulated (Figures 6F and 6G). The more significant
E-specific readout in the K/L LT-HSC fraction relative to total
LSK cells was probably due to the generally high level of MkE
priming in this cell population (Mansson et al., 2007). The rela-
tively low level of Cebpa expression in the LT-HSC fraction
cells (CD45.2+) (top row) and a distribution of myeloid (Mac 1+), B (B220+), and
T cell lineages (CD4/CD8+) within engrafted CD45.2+ cells. Percentages
indicate the proportion of gated populations within CD45.2+ cells.ancer Cell 16, 390–400, November 3, 2009 ª2009 Elsevier Inc. 395
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subpopulation of LT-HSCs. The altered lineage-specific gene
expression pattern indicated that this could be addressed by
measuring single-cell E-lineage priming in the LT-HSC popula-
tion. If E-priming was expanded to the majority of cells, this
would be consistent with Cebpa being expressed throughout
the compartment. We tested this using KK LT-HSCs (the geno-
type where the effect of lineage priming was stronger), and found
that the number of Gata1, Epor, and Klf1 expressing cells was
strongly increased relative to wild-type control cells, whereas
expression of Csf3r (which is a C/EBPa target gene encoding
the G-CSF-R) was decreased (Figure S4). In particular Gata1
expression was observed in virtually all KK LT-HSCs. This
indicated that the effect of Cebpa mutation was fairly uniform
across the LT-HSC compartment and showed that the loss of
Figure 5. Different Myeloid Maturation of
Cebpa Mutant AMLs
(A and B) Increased blast cells occurrence in PB
(A) and BM (B) in leukemic mice as analyzed by
May Gru¨nwald/Gimsa staining of peripheral blood
smears and BM cytospins. Scale bars represent
20 mm.
(C and D) Altered splenic architecture in L/L, K/L,
and K/K M leukemic animals as analyzed by
H&E staining of splenic sections (original magnifi
cation, 103) and infiltration of leukemic MPO+
cells into spleen as seen in myeloperoxidase
(MPO) staining of spleen tissue sections (D). Scale
bars represent 1 mm.
(E) Representative FACS analysis of BM cells in
control and leukemic mice at 8 months after trans
plantationwithFLcells ofdifferentcebpagenotypes
(indicated inA).Donorcells (CD45.1CD45.2+)were
analyzed for the surface expression of c Kit and
Mac 1. Thepercentagesof eachpopulation relative
to the total live BM cells are shown next to each
gate.
(F) Flow cytometric analysis of splenocytes iso
lated from control and leukemic mice revealed
infiltration of myeloid Mac 1+Gr 1+ cells into
spleen. The frequency of gated population relative
to total live splenocytes is shown next to the gate.
(G) Tumor phenotype distribution in mice trans
planted with K/K (n = 12), K/L (n = 22), and L/L
(n = 14) cells.
C/EBPa function led to altered lineage
priming also at the single-cell level.
DISCUSSION
The results presented here provide direct
genetic evidence that leukemogenic
Cebpamutations induce the lossof quies-
cence in, and consequently expansion
of, premalignant HSCs/MPPs in a cell-
intrinsic manner. In addition, we show
that the presence of C-terminal Cebpa
mutations skews the lineage program-
ming of HSCs, decreasing myeloid gene
expression and increasing erythroid-
specific gene expression, concomitant with a subsequent
myeloid differentiation defect, providing a direct link between
expression of lineage-specific programs in HSCs and their
lineage potential. Finally, we find that themost efficient leukemo-
genesis occurs when premalignant HSC expansion (induced by
C-terminal Cebpa mutation) is combined with residual myeloid
lineage commitment (maintained by the N-terminal Cebpamuta-
tion), providing a model for CEBPA mutant leukemia develop-
ment that explains the prevalence of tumors carrying one of
each of the two mutation types.
Modeling of human leukemogenesis in the mouse has relied to
a large extent on the use of retroviral transduction to introduce
oncogenes into the stem cell/progenitor compartment. Although
this is a powerful system for the verification of leukemogenic
potential and analysis of oncogene synergy, it has limitations396 Cancer Cell 16, 390–400, November 3, 2009 ª2009 Elsevier Inc.
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heterogeneity of transduced populations and nonphysiological
levels of expression. The use of knockin mutagenesis has been
employed to study the MLL-AF9, RUNX1-ETO, CBFb-SMMHC,
and FLT3-ITD mutations (Chen et al., 2008; Higuchi et al.,
2002; Kuo et al., 2006; Lee et al., 2007) in addition to C/EBPa
(Kirstetter et al., 2008). Only in the case of CBFb-SMMHC was
the effect of the mutation of HSC function evaluated, and repo-
pulating activity observed to be decreased (Kuo et al., 2006).
The effect of Runx1-Eto on HSC function was not analyzed
(Higuchi et al., 2002); however, using the same genetic model,
we have observed no expansion or competitive advantage of
HSCs expressing this oncogene (E.M. and C.N., unpublished
data). The Flt3-ITD mutation did in its homozygous state lead
Figure 6. Leukemogenic Cebpa Mutations Control HSC Myeloid Gene Expression and Committed Myeloid Progenitor Formation
(A) Flow cytometric analysis of myeloid differentiation potential of FL derived cells of different genotypes at 4.5 weeks after transplantation. Lineage/Sca 1/
IL7Ra cells were gated and analyzed for the surface expression of c Kit, CD150, and FcgRII/III for separation of GMPs (c Kit+CD150FcgRII/III+) from
pre GM (c Kit+CD150FcgRII/III) progenitors. Representative contour plots for each genotype are shown.
(B) Average values for five or more animals per genotype analyzed as in (A) are shown in graph. Error bars indicate standard deviations.
(C) BM cells from transplanted animals were stained for CD45.1, CD45.2, Mac 1, and B220 expression. The distribution of allotypes was analyzed for the B220+
(right panels) and Mac 1+ (left panels) experimental population. Numbers indicate the percentage of the gated populations.
(D and E) GSEA analysis of myeloid (upper panels) and (E) erythroid (lower panels) gene expression in Cebpa mutant LSK populations. Each population was
compared individually with WT control profiles. The NES and p values are indicated on each plot.
(F and G) Similar analysis as in (D) and (E) for K/L LT HSCs.Cancer Cell 16, 390–400, November 3, 2009 ª2009 Elsevier Inc. 397
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this case (Lee et al., 2007). Both LSK expansion and leukemia
was observed in the case of Mll-Af9, but in a noncompetitive
setting (Chen et al., 2008). The present study may therefore
provide an example of a leukemogenic mutation that confers
a selective advantage to mutant HSCs in a competitive situation.
At the cellular level, HSCs carrying Cebpa K/K and K/L geno-
types were found to evade the normal homeostatic control
of HSC numbers: the mutant population expanded in an other-
wise wild-type bone marrow environment, demonstrating that
expansion is a cell intrinsic property conferred by the Cebpa
mutation. This expansion was associated with decreased quies-
cence of the LSK population. Importantly, the LT-HSC enriched
LSKCD150+Flt3 subset showed increased cycling in the K/K
and K/L Cebpa genotypes. The expansive phenotype was asso-
ciated with downregulation of gene expression normally associ-
ated with the quiescent state (Venezia et al., 2004). These results
identify C/EBPa as a cell-intrinsic negative regulator of HSC cell-
cycle progression and homeostasis, and indicate that C/EBPa
regulates a quiescence-associated gene expression program.
It is clear, however, that expansion of FL HSC is not affected
by Cebpa mutations because similar numbers of HSCs were
present in FL from the various Cebpa genotypes. The prolifera-
tion of FL HSCs is very rapid with a cycling time of ca. 11 hr
(Nygren et al., 2006), as opposed to the highly quiescent HSC
in the BM. Given that Cebpamutation seems to affect principally
quiescence-associated gene expression, the lack of quiescence
of FL-HSCs could therefore explain the absence of Cebpa
mutant FL expansion.
In addition, our results provide additional insights into the role
of lineage commitment in myeloid leukemogenesis. It has been
assumed that AML LICs were phenotypically similar to HSCs
(Bonnet and Dick, 1997; Lapidot et al., 1994), and that the unili-
neage property of most AMLs was due to lineage bias during LIC
differentiation. However, recent results indicate that LICs in
human AML may include committed progenitors in many cases
(Taussig et al., 2008), a fact previously obscured by their selec-
tive elimination by the residual immune system of the NOD/
SCID host when conjugated with the anti-CD38 antibody used
to discriminate progenitors from stem cells. The results obtained
here as well as in earlier studies of myeloid leukemias arising in
Cebpamutant knockin mice (Kirstetter et al., 2008), or after viral
transduction of MOZ-TIF2 (Huntly et al., 2004) or MLL fusion
proteins (Cozzio et al., 2003; Somervaille and Cleary, 2006), all
support the ability of committed progenitors to sustain AML. In
these leukemias, the mutation directly affects myeloid progeni-
tors by increasing their proliferative capacity (but not that of,
for example, megakaryocyte-erythroid progenitors [Huntly
et al., 2004; Kirstetter et al., 2008]), indicating that lineage selec-
tion occurs through the specific effect of these mutations on the
myeloid progenitors, leading to preferential generation of a
myeloid unilineage LIC. This view is further supported by our
recent finding that Cebpamutations introduce a myeloid lineage
bias in leukemias arising after retroviral insertion mutagenesis
(Hasemann et al., 2008). This model does not require that the
mutations instruct HSCs to undergo myeloid lineage commit-
ment. In fact, the most highly leukemogenic combination of
Cebpa mutations (K/L genotype) impairs myeloid lineage
commitment. As previously demonstrated, homozygosity (but398 Cancer Cell 16, 390–400, November 3, 2009 ª2009 Elsevier Incnot heterozygosity) for leukemogenic Cebpa mutations selec-
tively confers a proliferative phenotype on committed myeloid
progenitors (Kirstetter et al., 2008), consistent with the idea
that the selective ability of these mutations to render committed
myeloid progenitors susceptible to transformation, and not their
lineage instructive properties, enables them to preferentially
cause unilineage myeloid leukemia.
Finally, our results demonstrate that C/EBPa can act at the
LT-HSC stage to regulate lineage-specific gene expression in
a global manner: loss of C/EBPa DNA binding activity led to
a coordinated downregulation of myeloid-specific gene expres-
sion (in the K/L and K/K LSK cells) and upregulation of erythroid-
specific genes (K/K LSK cells and K/L LT-HSCs). The disruption
of HSC lineage programming precedes and parallels the subse-
quent defect inmyeloid lineage commitment, providing evidence
that HSC lineage priming is a direct determinant of downstream
lineage potential. In this model, the more severe lineage commit-
ment defect of the K/K HSCs may be explained by the combined
downregulation of the myeloid and upregulation of the erythroid
program, leading to a virtually complete bias away from myeloid
progenitor formation. It is interesting to note that comparison
betweenCEBPAmutantandnonmutantAMLrevealed thatseveral
erythroid-specific genes, including GATA1 and EPOR, were en-
riched in theCEBPAmutantcases (Marcuccietal., 2008).Although
caution needs to be applied in comparison to the present data
because the cell populations sampled are very different (purified
stem cells versus bulk tumor), this indicates thatCEBPAmutation
leads to derepression of erythroid gene expression in humanAML,
andpossiblyalsoerythroidbiasofprogenitor formation. This issue,
however, clearly needs further investigation.
In conclusion, we find that the clinical pattern of CEBPAmuta-
tions can be explained by the ability of biallelic N- and C-terminal
mutations to expand premalignant stem cells, combinedwith the
residual capacity to commit to the myeloid lineage. At a more
general level, these results demonstrate that the actions of
leukemogenic mutations are not confined to the final trans-
formed cell population: the processes that select the clinical
CEBPAmutation pattern (HSC expansion, lineage commitment)
affect cells located upstream of the final transformed progenitor
in the hematopoietic hierarchy. Thus, critical functions of onco-
genic mutations may be executed prior to actual cellular trans-
formation, and in cells that reside upstream of the final trans-
formed cell in the differentiation hierarchy.
EXPERIMENTAL PROCEDURES
Mouse Strains
The Cebpa Lp30 allele has been described previously. The K313KK mutation
was generated by inserting an additional lysine into position 314 in the C/EBPa
coding sequence, with the targeting strategy previously described (Porse
et al., 2001). Mouse lines were maintained on a mixed C57Bl/6 129/Ola back
ground (ca. 75% C57Bl/6 and 25% 129/Ola) under SPF conditions, according
to EMBL institutional and Italian National guidelines. All procedures were
approved by the EMBL Monterotondo Ethical Committee.
Bone Marrow Transplantation
E14.5 FL were obtained from intercrosses of CebpaL/+ and CebpaK/+ mice, as
appropriate. FL cell suspensions were prepared by mechanically disrupting
FLs passing through the 18 G needle in HBSS 2% fetal calf serum (FCS) and
cryopreserved in freezing media composed of 70% FCS, 10% dimethyl sulf
oxide, and 20% IMDM). CD45.1/2 recipients were generated by intercrossing.
Cancer Cell
HSC Expansion in C/EBPa Mutant AMLC57Bl/6 CD45.1 (Harlan) and C57Bl/6 CD45.2 (EMMA, Monterotondo, Italy)
mice,and lethally irradiatedasdescribed (Kirstetter etal., 2008). 125,000FLcells
(CD45.2) were cotransplanted with 500,000 competitor BM cells (CD45.1).
For transplantation of leukemic cells, 1 5.000 sorted leukemia cells (CD45.2)
were cotransplanted with 250,000 1,000,000 competitor cells (CD45.1).
Flow Cytometry and Cell Sorting
Cell sorting and flow cytometric analysis were performed essentially as
described elsewhere (Kirstetter et al., 2008). Details of staining protocols and
antibody dilutions can be found in Supplemental Experimental Procedures.
Real-Time PCR Analysis
For measurement of mRNA quantitative real time polymerase chain reaction
(RT PCR), total RNA was isolated with an RNeasy mini kit (QIAGEN) from puri
fied hematopoietic stem cell fractions, digested with DNase I for removal of
genomic DNA contamination, and used for reverse transcription with oligo(dT)
primer according to the manufacturer’s instructions (T primed First Strand Kit,
Amersham Biosciences). Triplicate RT PCR reactions were performed with
100 cell equivalents of RNA and normalized to Hprt1 (hypoxanthine guanine
phosphoribosyl transferase 1) with TaqMan probes and TaqMan universal
PCRmaster mix according to the manufacturer’s instructions (Applied Biosys
tems, Hammonton, NJ). Fold expression relative to Hprt1 was calculated with
the comparative Ct (2dCt) method.
Histology
Sections of spleen, liver, lung, or kidneywere prepared as described elsewhere
(Porse et al., 2001) and stainedwith hematoxylin eosin (H&E) or used for immu
nohistochemistry with rabbit anti MPO (A0398; DAKO) as primary antibody.
Binding of primary antibodies was detected with an Envision+ HRP (DAB)
detection kit (DAKO), in accordance with the manufacturer’s recommenda
tions. After that, the sections were counterstained with hematoxylin.
Microarray Analysis
Total RNA from sorted CD45.1CD45.2+Lin Sca 1+c Kit+ (LSK) cells from
CD45.1/2 mice competitively transplanted with CD45.2 experimental and
CD45.1 competitor bonemarrow (2 5000 cells/sample) was hybridized to Affy
metrix MOE430 2.0 microarrays after two rounds of linear amplification by the
SCIBLU genomics facility (University of Lund, Sweden) and analyzed as
described previously (Kirstetter et al., 2008), except that data were clustered
by K means. Normalized data were filtered for minimal expression and then
tested for gene set enrichment using GSEA v2.0 (Subramanian et al., 2005)
(http://www.broad.mit.edu/gsea/). Each genotype (KK, KL, and LL for LSK;
KL for LT HSC) was compared with the control in a separate test. Gene sets
were curated from Venezia et al. (2004) and Mansson et al. (2007). The Mk
and E specific gene sets were generated from the MkE gene set (Mansson
et al., 2007) by selectinggenes showinga>1.5 foldoverexpression inMkversus
E and E versus Mk differentiated cells, respectively. GSEA enrichment results
were filtered for statistical significanceusing anominal p value threshold of 0.05.
Lineage Priming
Single cell lineage priming analysis was carried out as previously described
(Adolfsson et al., 2005; Mansson et al., 2007).
Statistical Analysis
Statistical significance was determined with Student’s t test, except for Ka
plan Meier survival comparisons, where the log rank test was used (calculated
with XLStat software; Addinsoft, Paris, France).
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